

DAFTAR PUSTAKA

- AAO. (2015). *Retina and Vitreous BCSC Sec-12*. San Fransisco.
- Amadio, M., Govoni, S., Pascale, A. (2016). Targeting VEGF in Eye Neovascularization: What's new? A comprehensive Review on Current Therapies and Oligonucleotide-Based Interventions Under Development. *Journal Pharmacological Research*. 103: 253–269.
- Agrahari, V., Mandal, A., Agrahari, V., Trinh H. M., Joseph, M., Ray, A., Hadji, H., Mitra, R., Pal, D., Mitra, A. K. (2016). A Comprehensive Insight on Ocular Pharmacokinetics. *Drug delivery and translational research*, 6(6), 735-754.
- Alnagdy, A. A., Abouelkheir, H. Y., El-Khouly, S. E., & Tarshouby, S. M. (2018). Impact of topical nonsteroidal anti-inflammatory drugs in prevention of macular edema following cataract surgery in diabetic patients. *International journal of ophthalmology*, 11(4), 616–622.
- Ang, W. J., Zunaina, E., Norfadzillah, A. J., Raja-Norliza, R. O., Julieana, M., Ab-Hamid, S. A., & Mahaneem, M. (2019). Evaluation of Vascular Endothelial Growth Factor Levels in Tears and Serum Among Diabetic Patients. *PLoS one*, 14(8), e0221481.
- Asrorudin, M. (2014). Dampak Gangguan Penglihatan dan Penyakit Mata Terhadap Kualitas Hidup Terkait Penglihatan (*Vision-Related Quality of Life*) pada Populasi Gangguan Penglihatan Berat dan Buta di Indonesia. Tesis. Fakultas Kedokteran Universitas Indonesia.
- Barañano, D. E. et al. (2009) Efficacy and pharmacokinetics of intravitreal nonsteroidal anti-inflammatory drugs for intraocular inflammation. *British J Ophthalmology*, 93(10),1387–1390. doi: 10.1136/bjo.2009.157297.
- Bayomy, N. R., & Elgouhary, S. M. (2018). Association Between Aqueous IL-6, TNF-A and VEGF With Diabetic Macular Edema. *The arab journal of laboratory medicine*, 43(3), 907 – 914.
- Blinder, K. J., Dugel, P. U., Chen, S., Jumper, J. M., Walt, J. G., Hollander, D. A., & Scott, L. C. (2017). Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO Study Report 1). *Clinical ophthalmology (Auckland, N.Z.)*, 11, 393–401.
- Brownlee, M. 2005. The pathobiology of diabetic complications: a unifying mechanism. *diabetes*, 54, 1615-1625.
- Cáceres-Del-Carpio, J., Costa, R. D., Haider, A., Narayanan, R. & Kuppermann, B. D. (2016). Corticosteroids: Triamcinolone, Dexamethasone and Fluocinolone. *Developments in ophthalmology*, 55, 221–231.
- Chatziralli, I.P., Sergentanis, T.N., Parikakis, E.A., Papazisis, L.E., Mitropoulos, P., Moschos, M. M. (2017) The Impact of Non-Steroidal Anti-Inflammatory Agents after Phacoemulsification on Quality of Life: A Randomized Study. *Ophthalmol Ther* (2017) 6:133–140.DOI 10.1007/s40123-016-0073-3
- Costagoggia, C., Agnifili, L., Arcidiacono, B., et al. (2012). Systemic thromboembolic adverse events in patients treated with antivitreal anti-

- VEGF drugs for neovascular age-related macular degeneration, *Expert Opin. Biol. Ther.* 12(10), pp. 1299-1313.
- Das U. N. (2016). Diabetic Macular Edema, Retinopathy and Age-Related Macular Degeneration as Inflammatory Conditions. *Archives of medical science*, 12(5), 1142–1157.
- Das, A., McGuire, P. G., & Rangasamy, S. (2015). Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Targets. *Ophthalmology*, 122(7), 1375–1394.
- Du, X., Edelstein, D., Rossetti, L., Fantus, I. G., Goldberg, H., Zlyadeh, F., Wu, J., Brownlee, M. (2000). Hyperglycemia-Induced Mitochondrial Superoxide Overproduction Activates the Hexosamine Pathway and Induces Plasminogen Activator Inhibitor-1 Expression by Increasing Sp1 Glycosylation. *Proceedings of the National Academy of Sciences of the United States of America (PNAS)*. Vol. 97, No. 22.
- Ehlers, J.P., Uchida, A., Hu, M., Figueiredo, N., Kaiser, P.K., Heier, J.S., Brown, M.D., Boyer, D.S., Do, D.V., Gibson, A., Saroj, N., Srivastava, S.K. (2019) Higher-Order Assessment of OCT in Diabetic Macular Edema from the VISTA Study: Ellipsoid Zone Dynamics and the Retinal Fluid Index. *Ophthalmology Retina*;3:1056-1066 by the American Academy of Ophthalmology.
- ElBendary, A., Elkannishy, A. H. (2018). Intravitreal Diclofenac Versus Intravitreal Bevacizumab in Persistent Diabetic Macular Edema: Anatomical And Functional Outcome. *Saudi Journal of Ophthalmology*, 32(4), 303-309.
- Fadhilah, N. (2018). Analisis Faktor Yang Berhubungan Dengan Kualitas Hidup Penderita Katarak Di Balai Kesehatan Mata Masyarakat Makassar. *Tesis Program Pascasarjana Universitas Hasanuddin Makassar*.
- Fajariyanti, Y., Widan, A., Johan, A. (2017). Perbedaan *Quality Of Life* Pada Penderita *Proliferative Diabetic Retinopathy* Dengan Dan Tanpa Laser *Panretinal Photocoagulation*. *Jurnal Kedokteran Diponegoro*. Volume 6, Nomor 2, April 2017.
- Falavarjani, K. G., and Nguyen, Q. D. (2013). Adverse Events and Complications Associated with Intravitreal Injection of anti-VEGF agents: A Review of Literature. *Eye*. 27, 787–794
- Fiebai, B., & Odogu, V. (2017). Intravitreal Anti Vascular Endothelial Growth Factor Agents in The Management of Retinal Diseases: An Audit. *The open ophthalmology journal*, 11, 315–321.
- Fogli, S., Mogavero, S., Egan, C. G., Del Re, M., Danesi, R. (2016). Pathophysiology and Pharmacological Targets of VEGF in Diabetic Macular Edema. *Journal Pharmacological Research*. 11.003.
- Funck, M., Schmidinger, G., Maar, N., Bolz, M., Benesch, T., Zlabinger, G. J., Schmidt-Erfurth, U. M. (2010). Angiogenic and Inflammatory Markers in The Intraocular Fluid of Eyes With Diabetic Macular Edema and Influence of Therapy with Bevacizumab. *RETINA*. 30:1412–1419.
- Gillies, M. C., Kuzniarz, M., Craig, J., Ball, M., Luo, W. & Simpson, J. M. 2005. Intravitreal triamcinolone-induced elevated intraocular pressure is

- associated with the development of posterior subcapsular cataract. *Ophthalmology*, 112, 139-143.
- Hammes, H.-P., Welp, R., Kempe, H.-P., Wagner, C., Siegel, E., Holl, R. W., Network, D. I. G. B. C. & Mellitus, D. (2015). Risk Factors for Retinopathy and DME in Type 2 Diabetes—Results from the German/Austrian DPV Database. *PloS one*, 10(7), e0132492.
- Hardianti, A. (2018). Kualitas Hidup Penderita Glaukoma Di Balai Kesehatan Mata Masyarakat Kota Makassar. *Tesis Program Pascasarjana Universitas Hasanuddin Makassar*.
- Hariprasad, S. M., Milier, W. F., Grassi, M., Green, J. L., Jager, R. D., Miller, L. (2007). Vision-related Quality of Life in Patients with Diabetic Macular Oedema. *British Journal of Ophthalmology*. 92:89–92.
- Hayati, F., Kartasmita, A., Rini, M., Karfiati, F. (2015). Measurement of the Cut Off Score of Visual Function Questionnaire on Vision Related Quality of Life to Predict Severity of Diabetic Retinopathy. *Ophthalmol Ina*; 41(3):272-278.
- Hillier, R. J., Ojaimi, E., Wong, D. T., Mak, M. Y. K., Berger, A. R., Kohly, R. P., Kertes, P. J., Forooghian, F., Boyd, S. R., Eng, K., Altomare, F., Giavedoni, L. R., Nisenbaum, R., & Muni, R. H. (2018). Aqueous Humor Cytokine Levels and Anatomic Response to Intravitreal Ranibizumab in Diabetic Macular Edema. *JAMA ophthalmology*, 136(4):382–388.
- Imazeki, M., Noma, H., Yasuda, K., Motohashi, R., Goto, H., Shimura, M. (2020) Anti-VEGF Therapy Reduces Inflammation in Diabetic Macular Edema. *Ophthalmic Research*. 1423-0259. DOI: 10.1159/000508953
- Iniguez, M.A., Rodriguez, A., Volpert, O.V., Fresno, M., Redondo, J.M. (2003) Cyclooxygenase-2: A Therapeutic Target In Angiogenesis. *TRENDS in Molecular Medicine*. Vol.9 No.2
- Jeon, S., Lee, W.K. (2014). Effect of intravitreal bevacizumab on diabetic macular edema with hard exudates. *Clinical Ophthalmology* 2014:8 1479-1486.
- Karmila, M. (2014). Kualitas Hidup Penderita Glaukoma di RSUP H. Adam Malik dan RSUD Pirngadi Medan Tahun 2012. Tesis. Departemen Ilmu Kesehatan Mata, FK Universitas Sumatera Utara.
- Kim, S. J., Flach, A. J. & Jampol, L. M. (2010). Nonsteroidal anti-inflammatory drugs in ophthalmology. *Survey of ophthalmology*, 55, 108-133.
- Lim, S.W., Sanchez, E.B., Kolic, M., Rogers, S.L., McAuley, A.K., Lim, L.L., Wickremasinghe, S.S. (2018) The Influence of Intravitreal Ranibizumab on Inflammation-associated Cytokine Concentrations in Eyes With Diabetic Macular Edema. *Investigation Ophthalmology Vision Science*. 59:5382–5390. <https://doi.org/10.1167/iovs.17-23325>
- Loftus, J. V., Sultan, M. B., Pleil, A. M. (2011). Changes in Vision- and Health-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Pegaptanib Sodium or Sham. *Investigative Ophthalmology and Visual Science (IOVS)*. Vol. 52, No. 10.
- Maldonado, R. M., Vianna, R. N., Cardoso, G. P., de Magalhães, A. V., Burnier, M. N. Jr. (2011) Intravitreal Injection of Commercially Available Ketorolac Tromethamine in Eyes with Diabetic Macular Edema

- Refractory to Laser Photocoagulation. *Current eye research*, 36(8), 768–773.
- Mangione, C. M., Lee, P. P., Gutierrez, P. R., Spritzer, K., Berry, S., Hays, R. D. Development of the 25-item National Eye Institute Visual Function Questionnaire. *Arch Ophthalmol.* 119:1050–8.
- Mann, I., Kaur, R., Khan, B., Matreja, P. S., Bhatnagar, R. N. (2015). Prevalence and Causes of Macular Edema and Its Correlation: an Observational Study. *Pacific Group of e-Journals (PaGe)*, AABS; 2(4)
- Medić, A., Jukić, T., Matas, A., Vukojević, K., Sapunar, A. & Znaor, L. (2017). Effect of Preoperative Topical Diclofenac on Intraocular Interleukin-12 Concentration and Macular Edema After Cataract Surgery in Patients with Diabetic Retinopathy: A Randomized Controlled Trial. *Croatian medical journal*, 58, 49-55.
- Mitchell, P., Bressler, N., Tolley, K., Gallagher, M., Petrillo, J., Ferreira, A., Wood, R., Bandello, F. (2013) Patient-Reported Visual Function Outcomes Improve After Ranibizumab Treatment in Patients With Vision Impairment Due to Diabetic Macular Edema: Randomized Clinical Trial. *JAMA Ophthalmology*, 131(10):1339-1347.
- Nguyen, Q. D., Tatlipinar, S., Shah, S. M., Haller, J. A., Quinlan, E., Sung, J., Campochiaro, P. A. (2006). Vascular Endothelial Growth Factor Is a Critical Stimulus for Diabetic Macular Edema. *American Journal of Ophthalmology*, 142(6), 961–969.
- Nurhayati, M., Amalia, I. N., Hafsa. (2019). Perbedaan Kualitas Hidup Pada Pasien Retinopati Diabetik Non-Proliferatif Berat Dan Retinopati Diabetik Proliferatif Di Poliklinik Vitreoretina Instalasi Rawat Jalan Pusat Mata Nasional Rumah Sakit Mata Cicendo Bandung. *Jurnal Sehat Masada*. Volume XIII Nomor 2.
- Okamoto, Y., Okamoto, F., Hiraoka, T., Oshika, T. (2014). Vision-Related Quality of Life and Visual Function Following Intravitreal Bevacizumab Injection for Persistent Diabetic Macular Edema after Vitrectomy. *Jpn J Ophthalmol*. DOI 10.1007/s10384-014-0323-7
- Ono, Y., Aoki, S., Ohnishi, K., Yasuda, T., Kawano, K. & Tsukada, Y. 1998. Increased serum levels of advanced glycation end-products and diabetic complications. *Diabetes research and clinical practice*, 41, 131-137.
- Pakneshan, P., Birsner, A.E., Adini, I., Becker, C.M., D'Amato, R.J. (2008) Differential Suppression of Vascular Permeability and Corneal Angiogenesis by Nonsteroidal Anti-inflammatory Drugs. *Investigative Ophthalmology & Visual Science*. Vol. 49, No. 9
- Pożarowska, D., & Pożarowski, P. (2016). The Era of Anti-Vascular Endothelial Growth Factor (VEGF) Drugs in Ophthalmology, VEGF and Anti-VEGF Therapy. *Central-European journal of immunology*, 41(3), 311–316.
- Rajendram, R., Fraser-Bell, S., Kaines, A., Michaelides, M., Hamilton, R. D., Esposti, S. D., Peto, T., Egan, C., Bunce, C., Leslie, R. D., Hykin, P. G. (2012) A 2-Year Prospective Randomized Controlled Trial of Intravitreal Bevacizumab or Laser Therapy (BOLT) in the Management of Diabetic Macular Edema. *Arch Ophthalmology*. 130(8):972-979.

- Reis, A. C. A., Vianna, R. N. G., Reis, R. S. M., Cardoso, G. P. (2010) Intravitreal Injection of Ketorolac Tromethamine in Patients with Diabetic Macular Edema Refractory to Retinal Photocoagulation. *Arq Bras Oftalmology* . 73(4) :338-42
- Romero-Aroca, P., Baget-Bernaldiz, M., Pareja-Rios, A., Lopez-Galvez, M., Navarro-Gil, R., & Verges, R. (2016). Diabetic Macular Edema Pathophysiology: Vasogenic versus Inflammatory. *Journal of diabetes research*, 17, 2156273.
- Russo, A., Costagliola, C., Delcassi, L., Parmeggiani, F., Romano, M. R. & Semeraro, F. (2013) Topical nonsteroidal anti-inflammatory drugs for macular edema. *Mediators of inflammation*, 2013.
- Saputro, A., Agni, A.N., Supanji. (2021) Perubahan Ketebalan Makula Sentral Pada Injeksi Intravitreal Ketorolak Dibandingkan Dengan Injeksi Intravitreal Bevacizumab Pada Pasien Edema Makula Diabetika.
- Santos, A.R., Costa, M.A., Schwartz, C., Alves, D., Figueira, J., Silva, R., Cunha-Vaz, J.G. (2018) Optical Coherence Tomography Baseline Predictors for Initial Best-Corrected Visual Acuity Response to Intravitreal Antivascular Endothelial Growth Factor Treatment in Eyes with Diabetic Macular Edema The CHARTRES study. *Retina* ;38(6):1110-1119.
doi: 10.1097/IAE.0000000000001687
- Schoenberger, S. D. and Kim, S. J. (2013). Non Steroidal Ant Inflammatory Drugs for Retinal Disease. *International Journal of Inflammation Hindawi Publishing Corporation*. Volume 2013, Article ID 281981, 8 pages
- Semeraro, F., Russo, A., Gambicorti, E., Duse, S., Morescalchi, F., Vezzoli, S., & Costagliola, C. (2015). Efficacy and Vitreous Levels of Topical OAINSs. *Expert Opinion on Drug Delivery*, 12(11), 1767-1782.
- Soheilian, M., Karimi, S., Ramezani, A., Peyman, G. A. (2010). Pilot Study Of Intravitreal Injection Of Diclofenac For Treatment Of Macular Edema Of Various Etiologies. *RETINA*, 30:509–515.
- Stefansson, E., Bek. T., Porta, M., Larsen, N., Kristinsson, J. K., and Agardh, E. (2000). Screening and prevention of diabetic blindness. *Acta Ophthalmologica Scandinavia*, 78(4), 374-385.
- Swamy, B. N., Chia, E., Wang, J. J., Rochtchina, E., Mitchell, P. (2009). Correlation between vision- and health-related quality of life scores. *Acta Ophthalmologica*. 87: 335–339.
- Tamura, M., Sebastian, S., Gurates, B., Yang, S., Fang, Z., Bulun, S.E. (2002) Vascular Endothelial Growth Factor Up-regulates Cyclooxygenase-2 Expression in Human Endothelial Cells. *The Journal of Clinical Endocrinology & Metabolism* 87(7):3504–3507.
- Tsilimbaris, M. K., Tsika, C., & Kymionis, G. D. (2016). Intravitreal Ketorolac for The Treatment of Chronic Cystoid Macular Edema After Cataract Surgery. *Therapeutics and clinical risk management*, 12, 177–182.
- Turkoglu, E. B., Celik, E., Aksoy, N., Bursali, O., Ucak, T., Alagoz, G. (2015). Changes in Vision Related Quality of Life in Patients with Diabetic Macular Edema: Ranibizumab or Laser Treatment? *Journal of Diabetes and Its Complications*. 29: 540–543.

- Urias, E. A., Urias, G. A., Monickaraj, F., McGuire, P., Das, A. (2017). Novel Therapeutic Targets in Diabetic Macular Edema: Beyond VEGF. *Vision research*, 139, 221-227.
- Wafapoor, H., McCluskey, J. (2006). Intravitreal Ketorolac as a Treatment of Diabetic and Non-Diabetic Macular Edema. *Investigative Ophthalmology & Visual Science (IOVS)*. Vol.47, 4252.
- Wahyuni, Y., Nursiswati, Anna, A. (2014). Kualitas Hidup berdasarkan Karakteristik Pasien Diabetes Melitus Tipe 2. Volume 2 Nomor 1. Fakultas Keperawatan Universitas Padjadjaran.
- Weih, L. M., Hassel, J. H., Keeffe, J. (2002). Assessment of the Impact of Vision Impairment. *Investigative Ophthalmology & Visual Science*, Vol. 43, No. 4.
- Wells, J. A., Glassman, A. R., Ayala, A. R., Jampol, L. M., Aiello, L. P., Antoszyk, A. N., Arnold-Bush, B., Baker, C. W., Bressler, N. M. & Browning, D. J. (2015). Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. *The New England journal of medicine*, 372, 1193-1203.
- Whynes, D. K. (2008). Correspondence between EQ-5D health state classifications and EQ VAS scores. *Health and Quality of Life Outcomes*, 6:94.
- Wolf, A., Coros, A., Bierer, J., Goncalves, S., *et al.* (2017). Quantitative evaluation of vision-related and health-related quality of life after endoscopic transsphenoidal surgery for pituitary adenoma. *Journal Neurosurgery*, 127:409–416.
- Yau, J. W., Rogers, S. L., Kawasaki, R., Lamoureux, E. L., Kowalski, J. W., Bek, T., Chen, S.-J., Dekker, J. M., Fletcher, A. & Grauslund, J. (2012). Global prevalence and major risk factors of diabetic retinopathy. *Diabetes care*, 35, 556-564.
- Zheng, Y., He, M., Congdon, N. (2012). The Worldwide Epidemic of Diabetic Retinopathy. *Indian Journal of Ophthalmology*, Vol. 60 No. 5.